Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2 CAR T Cells + Checkpoint Blockade in Advanced Sarcoma (HEROS 3.0)
NCT04995003Phase 1Recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Dec 2021
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of HER2-CAR-T cells in sarcoma (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Dose-Limiting Toxicity Rate at 42 days. Started Dec 2021; status: recruiting.
02
Drugs
HER2-CAR-T cells
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT04995003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04995003.